Replimune Investors Face Securities Lawsuit Following FDA Rejection

The complaint filed in the United States District Court for the District of Massachusetts centers on the gap between management's public optimism and the FDA's eventual rejection of the biologics license application. While Replimune reported that the agency viewed its resubmission as a complete response, the FDA later disclosed that the company failed to address critical study-design issues previously communicated in earlier interactions. The firm relied on an early, unplanned analysis of only 40 patients—just 10% of the planned enrollment—to support its application.

Market confidence evaporated rapidly following the April 2026 disclosure. Shares, which had peaked at $10.73 in December 2025, plummeted to $1.70 by mid-April. Joseph E. Levi, representing the plaintiffs, contends that the sequence of corporate announcements created a false impression of imminent approval, leaving shareholders exposed to significant losses when the true regulatory status was revealed. Investors who purchased Replimune securities during the specified class period have until October 5, 2026, to seek lead plaintiff status as the case proceeds under the Private Securities Litigation Reform Act.